Literature DB >> 7105389

The predictive value of the lymphocyte transformation test in isoniazid-associated hepatitis.

R J Warrington, S McPhilips-Feener, W J Rutherford.   

Abstract

Sixty-one patients receiving isoniazid (INH) for chemotherapy or chemoprophylaxis were assessed by the lymphocyte-transformation test (LTT) shortly after starting treatment. Thirty-eight per cent exhibited stimulation with INH, isonicotinic acid (INA) or human-serum albumin conjugates of these haptens. In the LTT-positive group, liver dysfunction subsequently developed in 58.8%, as compared to 22.7% in the LTT-negative group (P less than 0.01). The difference was not accountable on the basis of age, ethnic background, sex or chemotherapy vs chemoprophylaxis. Although there was an excess of alcohol abusers in the LTT-positive group, the probability of developing liver dysfunction amongst alcohol abusers in that group was twice as great as for LTT-negative alcohol abusers. The specificity of the LTT in predicting liver damage was 83-90% (depending upon the criteria used for determining positivity), while the sensitivity of the test was only 50%.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105389     DOI: 10.1111/j.1365-2222.1982.tb02521.x

Source DB:  PubMed          Journal:  Clin Allergy        ISSN: 0009-9090


  10 in total

1.  Lack of liver injury in Wistar rats treated with the combination of isoniazid and rifampicin.

Authors:  Imir G Metushi; Jack Uetrecht
Journal:  Mol Cell Biochem       Date:  2013-10-23       Impact factor: 3.396

Review 2.  Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management.

Authors:  M Mosedale; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  2017-01-11       Impact factor: 6.875

3.  Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response.

Authors:  Jessica Whritenour; Mira Ko; Qing Zong; Jianying Wang; Karrie Tartaro; Patricia Schneider; Ellen Olson; Maria Van Volkenburg; Jose Serrano; Paul Hayashi; Robert Fontana; Naga Chalasani; Herbert L Bonkovsky
Journal:  J Immunotoxicol       Date:  2017-12       Impact factor: 3.000

Review 4.  The transformation in biomarker detection and management of drug-induced liver injury.

Authors:  Rachel J Church; Paul B Watkins
Journal:  Liver Int       Date:  2017-05-08       Impact factor: 5.828

5.  Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure.

Authors:  Imir G Metushi; Corron Sanders; William M Lee; Jack Uetrecht
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

Review 6.  Mechanism of isoniazid-induced hepatotoxicity: then and now.

Authors:  Imir Metushi; Jack Uetrecht; Elizabeth Phillips
Journal:  Br J Clin Pharmacol       Date:  2016-02-25       Impact factor: 4.335

7.  The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats.

Authors:  John Mach; Aniko Huizer-Pajkos; Sarah J Mitchell; Catriona McKenzie; Leo Phillips; Alice Kane; Brett Jones; Rafael de Cabo; Victoria Cogger; David G Le Couteur; Sarah N Hilmer
Journal:  Fundam Clin Pharmacol       Date:  2015-11-09       Impact factor: 2.748

8.  miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model.

Authors:  Merrie Mosedale; J Scott Eaddy; O Joseph Trask; Natalie S Holman; Kristina K Wolf; Edward LeCluyse; Brenton R Ware; Salman R Khetani; Jingtao Lu; William J Brock; Sharin E Roth; Paul B Watkins
Journal:  Toxicol Sci       Date:  2018-01-01       Impact factor: 4.849

9.  Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats.

Authors:  Imir G Metushi; Tetsuya Nakagawa; Jack Uetrecht
Journal:  Chem Res Toxicol       Date:  2012-10-16       Impact factor: 3.739

Review 10.  Mechanistic Studies of Idiosyncratic DILI: Clinical Implications.

Authors:  Jack Uetrecht
Journal:  Front Pharmacol       Date:  2019-07-26       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.